Background: Mitomycin C (MMC) inhibits fibroblast proliferation. The objective of this study was to determine the efficacy of MMC in reducing frontal ostium stenosis after endoscopic sinus surgery.
Methods: A prospective open pilot study was conducted in 28 patients who had undergone one or more previous surgical interventions for frontal sinusitis. MMC solution was applied to the frontal ostial region via an endoscopic or combined endoscopic and external approach. Patency of the frontal ostium was evaluated endoscopically during regular follow-up. If restenosis was observed further, endoscopic application of MMC was undertaken.
Results: There were 17 men and 11 women (mean age, 51.7 years; range, 26-86 years). Mean number of applications was 1.5 (range, 1:3). Mean follow-up was 19 months (range, 6-32 months). Patency rate was 86%.
Conclusion: Mitomycin appears to have an important role in reducing postoperative scarring, which may obviate the need for repeated and more extensive surgery.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.2500/ajr.2006.20.2917 | DOI Listing |
Sci Rep
December 2024
Respiratory Medicine Unit, Department of Clinical Medicine and Surgery, Monaldi Hospital- AO dei Colli, Federico II University of Naples, Via L. Bianchi, 5, 80131, Naples, Italy.
Quantitative assessment of the extent of radiological alterations in interstitial lung diseases is a promising field of application that goes beyond the limitations of qualitative scoring. Analysis of density histograms, i.e.
View Article and Find Full Text PDFDig Liver Dis
December 2024
Gastroentrology Department, Hospital Germans Trias i Pujol, 08916 Badalona, Catalonia, Spain; CIBEREHD, Madrid, Spain; Departament de Medicina, Universitat Autònoma de Barcelona, Catalonia, Spain. Electronic address:
Background: Endoscopic evaluation 6-12 months after ileocolonic resection (ICR) in Crohn's disease (CD) is advised to assess the development of postoperative recurrence (POR) but no further recommendations are available for long-term monitoring if no POR is noticed.
Methods: Prospective, open-label, study including asymptomatic patients with CD and ICR in whom no POR was observed at the last endoscopic evaluation. Patients were followed-up for two years and ileocolonoscopy was performed by means of a faecal calprotectin (FC)-based strategy.
JAMA Netw Open
December 2024
Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
Importance: Serial circulating tumor DNA (ctDNA) has emerged as a routine surveillance strategy for patients with resected colorectal cancer, but how serial ctDNA monitoring is associated with potential curative outcomes has not been formally assessed.
Objective: To examine whether there is a benefit of adding serial ctDNA assays to standard-of-care imaging surveillance for potential curative outcomes in patients with resected colorectal cancer.
Design, Setting, And Participants: In this single-center (City of Hope Comprehensive Cancer Center, Duarte, California), retrospective, case cohort study, patients with stage II to IV colorectal cancer underwent curative resection and were monitored with serial ctDNA assay and National Cancer Center Network (NCCN)-guided imaging surveillance from September 20, 2019, to April 3, 2024.
JAMA Netw Open
December 2024
Department of Radiation Oncology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Importance: Radiotherapy (RT) plan quality is an established predictive factor associated with cancer recurrence and survival outcomes. The addition of radiologists to the peer review (PR) process may increase RT plan quality.
Objective: To determine the rate of changes to the RT plan with and without radiology involvement in PR of radiation targets.
Pediatr Nephrol
December 2024
Department of Pediatric Nephrology, Great North Children Hospital, Newcastle Upon Tyne, UK.
Background: Optimal dosing of rituximab when given with mycophenolate mofetil (MMF) for frequently relapsing nephrotic syndrome/steroid-dependent nephrotic syndrome (FRNS/SDNS) remains uncertain.
Methods: This was a prospective, non-inferiority, open-label randomized controlled multicentre study. Children (2-18 years old) with difficult FRNS/SDNS were randomized to group A (rituximab 375 mg/m once) or group B (rituximab 375 mg/m twice; 7-14 days apart) followed by continuous MMF and 3 months of tapered steroids.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!